Actinium Pharmaceuticals, Inc. is a biopharmaceutical company. It is focused on developing Antibody Radiation-Conjugates, which combine the targeting ability of antibodies with the cell killing ability of radiation. Its product pipeline includes Iomab-B, Actimab-A, and Actimab-M. The company was founded in 1993 and is headquartered in New York, NY.